Key Points
- Atul Dandekar sold 7,500 shares of Maze Therapeutics (NASDAQ:MAZE) on April 29 at an average price of $25.37 for a total of $190,275, reducing his ownership by 41.66% to 10,503 shares; the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
- MAZE opened at $27.27, trades in a 52-week range of $8.24–$53.65, has a market cap of about $1.36 billion and a negative P/E of -8.44, with 50-day and 200-day moving averages near $36.92 and $38.05 respectively.
- Analyst sentiment is largely positive with a consensus rating of Buy and an average price target of $66.00, though individual price targets and ratings vary widely across firms.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the company's stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the transaction, the insider owned 10,503 shares of the company's stock, valued at approximately $266,461.11. The trade was a 41.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Maze Therapeutics Stock Performance
Shares of MAZE stock opened at $27.27 on Friday. Maze Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $53.65. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -8.44 and a beta of 2.52. The firm has a fifty day moving average of $36.92 and a 200-day moving average of $38.05.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. On average, sell-side analysts predict that Maze Therapeutics, Inc. will post -2.59 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Truist Financial dropped their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 14th. HC Wainwright increased their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, March 25th. Wedbush increased their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a research note on Monday, March 16th. Mizuho raised Maze Therapeutics to a "strong-buy" rating in a report on Wednesday, March 11th. Finally, Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $66.00.
View Our Latest Stock Analysis on MAZE
Institutional Investors Weigh In On Maze Therapeutics
Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth about $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth about $43,000. California State Teachers Retirement System increased its position in shares of Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock worth $55,000 after purchasing an additional 766 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after purchasing an additional 738 shares in the last quarter.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
